期刊
BLOOD REVIEWS
卷 49, 期 -, 页码 -出版社
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.blre.2021.100824
关键词
Chronic lymphocytic leukaemia; Richter's transformation; Ibrutinib; Venetoclax; TP53 disruption; Genetics
类别
资金
- Ministry of Health, Czech Republic conceptual development of research organization [0098892]
- Internal Grant Agency of Palacky University Olomouc [IGA_LF_2021_001, IGA_LF_2021_015]
Richter transformation (RT) refers to the development of aggressive lymphoma in patients with chronic lymphocytic leukaemia (CLL), most commonly diffuse large B-cell lymphoma (DLBCL). RT incidence is lower in CLL patients treated with novel agents, but higher in patients with TP53 disruption.
Richter transformation (RT) is the development of aggressive lymphoma - most frequently diffuse large B-cell lymphoma (DLBCL) and rarely Hodgkin lymphoma (HL) - arising on the background of chronic lymphocytic leukaemia (CLL). Despite recent advances in CLL treatment, RT also develops in patients on novel agents, usually occurring as an early event. RT incidence is lower in CLL patients treated with novel agents in the front line compared to relapsed/refractory cases, with a higher incidence in patients with TP53 disruption. The genetic heterogeneity and complexity are higher in RT-DLBCL than CLL; the genetics of RT-HL are largely unknown. In addition to TP53, aberrations in CDKN2A, MYC, and NOTCH1 are common in RT-DLBCL; however, no distinct RT-specific genetic aberration is recognised yet. RT-DLBCL on ibrutinib is frequently associated with BTK and PLCG2 mutations. Here, we update on genetic analysis, diagnostics and treatment options in RT in the era of novel agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据